Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM282 in NASH
NCT02443116Phase 2Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Jul 2015
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of aldafermin in Nonalcoholic steatohepatitis (NASH), sponsored by NGM Biopharmaceuticals. Started Jul 2015; status: completed.
02
Drugs
aldafermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02443116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443116.